RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted drug boost survival in Hard-to-Treat lymphoma?
Disease control OngoingThis phase 3 trial tests whether adding brentuximab vedotin to two standard drugs (lenalidomide and rituximab) helps people with diffuse large B-cell lymphoma that has returned or not improved after at least two prior treatments. About 239 participants will receive either the add…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New pill shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests an experimental oral drug, CC-99282, in people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is given alone or with other lymphoma medicines. The main goals are to check safety and find the best dose, while also seeing …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental drug brincidofovir targets Hard-to-Treat lymphomas
Disease control TerminatedThis study tests an experimental drug called brincidofovir in people with lymphoma (a type of blood cancer) that has returned or not improved after standard treatments. The trial has two parts: first, finding a safe dose in up to 18 people with various lymphomas, then testing tha…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: SymBio Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo aims to tackle tough lymphoma
Disease control OngoingThis study tests a modified intravenous dosing schedule of tafasitamab combined with oral lenalidomide in 53 adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for a stem cell transplant. The main goal is to evaluate safety and how the drug move…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Lymphoma combo drug trial pulled before it even started
Disease control TerminatedThis study aimed to test the drug selinexor combined with other treatments for people with a type of blood cancer called diffuse large B-cell lymphoma that had come back or stopped responding to therapy. The trial was planned in two phases to first find the safest dose and then c…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Blood test may spot cancer return weeks earlier after CAR-T
Knowledge-focused OngoingThis study tracks 40 patients with aggressive B-cell lymphoma who have received CAR-T cell therapy. Researchers take a blood sample 7 days after treatment to look for leftover tumor DNA. The goal is to see if they can report results within 3 weeks, giving doctors a head start to …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC